NASDAQ : INVA
Innoviva, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 21.31 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 1.54B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 1.53B |
| Enterprise Value | 1.29B |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 72.25M |
| Shares Outstanding | 72.25M |
| Shares Change (YoY) | +0.03% |
| Shares Change (QoQ) | -13.47% |
| Owned by Insiders (%) | 0.75% |
| Owned by Institutions (%) | 101.65% |
| Float | 67.65M |
Ratios
| Measure | Value |
|---|
| PE Ratio | 4.93 |
| Forward PE | 10.99 |
| PS Ratio | 3.48 |
| Forward PS | 3.27 |
| PB Ratio | 1.25 |
| P/TBV Ratio | 1.47 |
| P/FCF Ratio | 8.09 |
| P/OCF Ratio | 8.01 |
| PEG Ratio | 3.66 |
Evratios
| Measure | Value |
|---|
| EV / Earnings | 3.60 |
| EV / Sales | 2.92 |
| EV / EBITDA | 6.58 |
| EV / EBIT | 7.61 |
| EV / FCF | 6.78 |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 16.01 |
| Quick Ratio | 14.65 |
| Debt / Equity | 0.27 |
| Debt / EBITDA | 1.68 |
| Debt / FCF | 1.75 |
| Interest Coverage | 9.26 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | 36.68% |
| Return on Assets (ROA) | 6.95% |
| Return on Invested Capital (ROIC) | 14.05% |
| Return on Capital Employed (ROCE) | 10.19% |
| Weighted Average Cost of Capital (WACC) | 6.06% |
| Revenue Per Employee | $2.77M |
| Profits Per Employee | $2.25M |
| Employee Count | 159 |
| Asset Turnover | 0.29 |
| Inventory Turnover | 2.73 |
Taxes
| Measure | Value |
|---|
| Income Tax | 62.16M |
| Effective Tax Rate | 14.82% |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 0.38 |
| 52-Week Price Change | +20.77% |
| 50-Day Moving Average | 20.99 |
| 200-Day Moving Average | 21.89 |
| Relative Strength Index (RSI) | 53.40 |
| Average Volume (20 Days) | 630,951 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 7.27M |
| Short Previous Month | 6.85M |
| Short % of Shares Out | 10.06% |
| Short % of Float | 10.74% |
| Short Ratio (days to cover) | 7.44 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 440.00M |
| Gross Profit | 319.75M |
| Operating Income | 168.79M |
| Pretax Income | 419.40M |
| Net Income | 357.24M |
| EBITDA | 195.39M |
| EBIT | 168.79M |
| Earnings Per Share (EPS) | $4.31 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 579.06M |
| Total Debt | 331.24M |
| Net Cash | 247.82M |
| Net Cash Per Share | $3.43 |
| Equity (Book Value) | 1.23B |
| Book Value Per Share | 16.98 |
| Working Capital | 706.30M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | 191.49M |
| Capital Expenditures | -2.05M |
| Depreciation & Amortization | 26.60M |
| Net Borrowing | -25,000 |
| Free Cash Flow | 189.44M |
| FCF Per Share | $2.62 |
Margins
| Measure | Value |
|---|
| Gross Margin | 72.67% |
| Operating Margin | 38.36% |
| Pretax Margin | 95.32% |
| Profit Margin | 81.19% |
| EBITDA Margin | 44.41% |
| EBIT Margin | 38.36% |
| FCF Margin | 43.06% |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -0.03% |
| Shareholder Yield | -0.03% |
| Earnings Yield | 20.30% |
| FCF Yield | 12.36% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $35.00 |
| Price Target Difference | 64.94% |
| Analyst Consensus | Buy |
| Analyst Count | 5 |
| Revenue Growth Forecast (3Y) | 6.96% |
| EPS Growth Forecast (3Y) | 12.37% |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | 3.27 |
| Piotroski F-Score | 6 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside | |